Arthur J. McCullough

Arthur J. McCullough

Auto-generated profile, based on publicly available information

Arthur J. McCullough

Department of Gastroenterology and Hepatology, Cleveland Clinic Foundation, Cleveland, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Hepatology
Verified
Journal Article
Closed access
PDF file
RORobert S. O'Shea
Robert S. O'Shea
SDSrinivasan Dasarathy
Srinivasan Dasarathy
AMArthur J. McCullough
Arthur J. McCullough

29 December 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
ASArun Sanyal
Arun Sanyal
SFScott Laurence Friedman
Scott Laurence Friedman
AMArthur J. McCullough
Arthur J. McCullough
LDLara Dimick‐Santos
Lara Dimick‐Santos
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease (CLD) in North America. It is a growing contributor to the burden of CDL requiring liver transplantation. Cirrhosis is also associated with an increased risk of hepatocellular cancer, which may occur even in the absence of cirrhosis in subjects with nonalcoholic steatohepatitis (NASH), the histological form of NAFLD associated with increased liver‐related mortality. The diagnosis of NASH currently requires a liver biopsy. There are also no U.S. Food and Drug Administration (FDA)‐approved therapies for NASH. Therefore, there is a need to develop better diagnostic and therapeutic strategies for patients with NASH, targeting both those with early‐stage disease as well as those with advanced liver fibrosis. There are unique challenges in the design of studies for these target populations. The long relatively asymptomatic time interval in the progression of NAFLD and NASH to cirrhosis and ultimately liver failure, along with gaps in knowledge regarding disease modifiers, combine to present significant challenges in trial design. Therefore, there is an urgent need to develop methods to identify the populations at particular risk of disease progression and validate endpoints that reflect meaningful changes in health status in this population. This article summarizes the discussion at a joint workshop held September 5 and 6, 2013 in Silver Spring, Maryland, sponsored by the FDA and the American Association for the Study of Liver Diseases to develop guidance on diagnostic and therapeutic modalities for NASH. (Hepatology2015;61:1392–1405)

1 February 2018 in Clinics in Liver Disease
Verified
Journal Article
Closed access
CLChristina C. Lindenmeyer
Christina C. Lindenmeyer
AMArthur J. McCullough
Arthur J. McCullough

1 January 2010 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
RORobert S O'SHea
Robert S O'SHea
SDSrinivasan Dasarathy
Srinivasan Dasarathy
AMArthur J McCullough
Arthur J McCullough
These recommendations provide a data-supported approach. They are based on the following: (i) a formal review and analysis of the recently published world literature on the topic (Medline search); (ii) American College of Physicians Manual for Assessing Health Practices and Designing Practice Guidelines (<!--bib1--> 1); (iii) guideline policies, including the American Association for the Study of Liver Diseases (AASLD) Policy on the development and use of practice guidelines and the AGA Policy Statement on Guidelines (<!--bib2--> 2); and (iv) the experience of the authors in the specified topic. Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care. They are intended to be flexible, in contrast to the standards of care, which are inflexible policies to be followed in every case. Specific recommendations are based on relevant published information. To more fully characterize the quality of evidence supporting the recommendations, the Practice Guideline Committee of the AASLD requires a Class (reflecting the benefit vs. risk) and Level (assessing the strength or certainty) of Evidence to be assigned and reported with each recommendation (Table 1, adapted from the American College of Cardiology and the American Heart Association Practice Guidelines) (<!--bib3--> 3,<!--bib4--> 4).

20 December 2011 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
MPMangesh R. Pagadala
Mangesh R. Pagadala
CZClaudia O. Zein
Claudia O. Zein
SDSrinivasan Dasarathy
Srinivasan Dasarathy
LYLisa M. Yerian
Lisa M. Yerian
RLRocio Lopez
Rocio Lopez
AMArthur J. McCullough
Arthur J. McCullough

22 March 2016 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
GGGeorge Boon Bee Goh
George Boon Bee Goh
AMArthur J. McCullough
Arthur J. McCullough